Bin-Chi Liao

发表

Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib

J. Yang, Chia‐Chi Lin, Bin-Chi Liao, 2017, Current Oncology Reports.

Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan

Jih-Hsiang Lee, Yih-Leong Chang, J. Shih, 2018, Journal of Cancer.

Exon-16-skipping HER2 as a novel mechanism of osimertinib-resistance in EGFR L858R/T790M-positive non-small-cell lung cancer.

D. Stetson, K. Thress, A. Markovets, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Computed tomographic characteristics for patients with unresectable gastric cancer harboring low-volume peritoneal carcinomatosis

K. Yeh, Chung-Yi Yang, Jau-Yu Liau, 2017, Medical Oncology.

Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis

Chun-Nan Chen, Tseng-Cheng Chen, J. Chia, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

CD73 Is Regulated by the EGFR-ERK Signaling Pathway in Non-small Cell Lung Cancer

J. Yang, Bin-Chi Liao, S. Griesing, 2021, AntiCancer Research.

Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.

Jih-Hsiang Lee, Yih-Leong Chang, J. Shih, 2019, European journal of cancer.

Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.

Jih-Hsiang Lee, J. Yang, Chia‐Chi Lin, 2017, Lung cancer.

Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors

Jih-Hsiang Lee, J. Yang, Chia‐Chi Lin, 2016, Journal of Biomedical Science.

Lung Cancer in Republic of China.

T. Chou, C. Chiu, Yuh-Min Chen, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients

J. Yang, Bin-Chi Liao, S. Griesing, 2019, Therapeutic advances in medical oncology.

Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors.

Jih-Hsiang Lee, J. Shih, Yeun-Chung Chang, 2017, Journal of the Formosan Medical Association = Taiwan yi zhi.

Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer

J. Yang, Chia‐Chi Lin, Bin-Chi Liao, 2015, Current opinion in oncology.

Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma.

M. Lai, J. Yang, A. Cheng, 2015, Clinical lung cancer.

First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments

J. Yang, Chia‐Chi Lin, Bin-Chi Liao, 2013, Drugs.

Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC

Jih-Hsiang Lee, J. Shih, J. Yang, 2020, JTO clinical and research reports.

Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors

Jie Yang, Jih-Hsiang Lee, Chia‐Chi Lin, 2016, Journal of Biomedical Science.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis

Jih-Hsiang Lee, J. Shih, J. Yang, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?

J. Yang, Chia‐Chi Lin, Bin-Chi Liao, 2018, Expert opinion on pharmacotherapy.

Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice

M. Lai, J. Yang, A. Cheng, 2016, Journal of Cancer.

Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH study.

J. Yang, Bin-Chi Liao, 2012, Translational lung cancer research.

Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis

R. Hong, H. Kao, Huai-Cheng Huang, 2022, BMC Cancer.

Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy

J. Shih, J. Yang, Chia‐Chi Lin, 2015, Therapeutic advances in medical oncology.

Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.

Yih-Leong Chang, J. Shih, Chen‐Tu Wu, 2020, The oncologist.

Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma

B. Goh, M. Chua, N. Iyer, 2023, Nature communications.

A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study)

S. Lim, Q. Ou, T. Reungwetwattana, 2023, Cancers.

Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors

J. Shih, Shang-Gin Wu, Chao-Chi Ho, 2023, Oncology.